Cargando…

Evaluation and comparison of short chain fatty acids composition in gut diseases

BACKGROUND: An altered (dysbiosis) and unhealthy status of the gut microbiota is usually responsible for a reduction of short chain fatty acids (SCFAs) concentration. SCFAs obtained from the carbohydrate fermentation processes are crucial in maintaining gut homeostasis and their determination in sto...

Descripción completa

Detalles Bibliográficos
Autores principales: Niccolai, Elena, Baldi, Simone, Ricci, Federica, Russo, Edda, Nannini, Giulia, Menicatti, Marta, Poli, Giovanni, Taddei, Antonio, Bartolucci, Gianluca, Calabrò, Antonino Salvatore, Stingo, Francesco Claudio, Amedei, Amedeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767983/
https://www.ncbi.nlm.nih.gov/pubmed/31576099
http://dx.doi.org/10.3748/wjg.v25.i36.5543
_version_ 1783455032319934464
author Niccolai, Elena
Baldi, Simone
Ricci, Federica
Russo, Edda
Nannini, Giulia
Menicatti, Marta
Poli, Giovanni
Taddei, Antonio
Bartolucci, Gianluca
Calabrò, Antonino Salvatore
Stingo, Francesco Claudio
Amedei, Amedeo
author_facet Niccolai, Elena
Baldi, Simone
Ricci, Federica
Russo, Edda
Nannini, Giulia
Menicatti, Marta
Poli, Giovanni
Taddei, Antonio
Bartolucci, Gianluca
Calabrò, Antonino Salvatore
Stingo, Francesco Claudio
Amedei, Amedeo
author_sort Niccolai, Elena
collection PubMed
description BACKGROUND: An altered (dysbiosis) and unhealthy status of the gut microbiota is usually responsible for a reduction of short chain fatty acids (SCFAs) concentration. SCFAs obtained from the carbohydrate fermentation processes are crucial in maintaining gut homeostasis and their determination in stool samples could provide a faster, reliable and cheaper method to highlight the presence of an intestinal dysbiosis and a biomarker for various gut diseases. We hypothesize that different intestinal diseases, such as celiac disease (CD), adenomatous polyposis (AP) and colorectal cancer (CRC) could display a particular fecal SCFAs’ signature. AIM: To compare the fecal SCFAs’ profiles of CD, AP, CRC patients and healthy controls, using the same analytical method. METHODS: In this cross-sectional study, we defined and compared the SCFAs’ concentration in fecal samples of 9 AP, 16 CD, 19 CRC patients and 16 healthy controls (HC). The SCFAs’ analysis were performed using a gas-chromatography coupled with mass spectrometry method. Data analysis was carried out using Wilcoxon rank-sum test to assess pairwise differences of SCFAs’ profiles, partial least squares-discriminate analysis (PLS-DA) to determine the status membership based on distinct SCFAs’ profiles, and Dirichlet regression to determine factors influencing concentration levels of SCFAs. RESULTS: We have not observed any difference in the SCFAs’ amount and composition between CD and healthy control. On the contrary, the total amount of SCFAs was significantly lower in CRC patients compared to HC (P = 0.044) and CD (P = 0.005). Moreover, the SCFAs’ percentage composition was different in CRC and AP compared to HC. In detail, HC displayed higher percentage of acetic acid (P value = 1.3 × 10(-6)) and a lower amount of butyric (P value = 0.02192), isobutyric (P value = 7.4 × 10(-5)), isovaleric (P value = 0.00012) and valeric (P value = 0.00014) acids compared to CRC patients. AP showed a lower abundance of acetic acid (P value = 0.00062) and higher percentages of propionic (P value = 0.00433) and isovaleric (P value = 0.00433) acids compared to HC. Moreover, AP showed higher levels of propionic acid (P value = 0.03251) and a lower level of isobutyric acid (P value = 0.00427) in comparison to CRC. The PLS-DA model demonstrated a significant separation of CRC and AP groups from HC, although some degree of overlap was observed between CRC and AP. CONCLUSION: Analysis of fecal SCFAs shows the potential to provide a non-invasive means of diagnosis to detect patients with CRC and AP, while CD patients cannot be discriminated from healthy subjects.
format Online
Article
Text
id pubmed-6767983
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-67679832019-10-01 Evaluation and comparison of short chain fatty acids composition in gut diseases Niccolai, Elena Baldi, Simone Ricci, Federica Russo, Edda Nannini, Giulia Menicatti, Marta Poli, Giovanni Taddei, Antonio Bartolucci, Gianluca Calabrò, Antonino Salvatore Stingo, Francesco Claudio Amedei, Amedeo World J Gastroenterol Observational Study BACKGROUND: An altered (dysbiosis) and unhealthy status of the gut microbiota is usually responsible for a reduction of short chain fatty acids (SCFAs) concentration. SCFAs obtained from the carbohydrate fermentation processes are crucial in maintaining gut homeostasis and their determination in stool samples could provide a faster, reliable and cheaper method to highlight the presence of an intestinal dysbiosis and a biomarker for various gut diseases. We hypothesize that different intestinal diseases, such as celiac disease (CD), adenomatous polyposis (AP) and colorectal cancer (CRC) could display a particular fecal SCFAs’ signature. AIM: To compare the fecal SCFAs’ profiles of CD, AP, CRC patients and healthy controls, using the same analytical method. METHODS: In this cross-sectional study, we defined and compared the SCFAs’ concentration in fecal samples of 9 AP, 16 CD, 19 CRC patients and 16 healthy controls (HC). The SCFAs’ analysis were performed using a gas-chromatography coupled with mass spectrometry method. Data analysis was carried out using Wilcoxon rank-sum test to assess pairwise differences of SCFAs’ profiles, partial least squares-discriminate analysis (PLS-DA) to determine the status membership based on distinct SCFAs’ profiles, and Dirichlet regression to determine factors influencing concentration levels of SCFAs. RESULTS: We have not observed any difference in the SCFAs’ amount and composition between CD and healthy control. On the contrary, the total amount of SCFAs was significantly lower in CRC patients compared to HC (P = 0.044) and CD (P = 0.005). Moreover, the SCFAs’ percentage composition was different in CRC and AP compared to HC. In detail, HC displayed higher percentage of acetic acid (P value = 1.3 × 10(-6)) and a lower amount of butyric (P value = 0.02192), isobutyric (P value = 7.4 × 10(-5)), isovaleric (P value = 0.00012) and valeric (P value = 0.00014) acids compared to CRC patients. AP showed a lower abundance of acetic acid (P value = 0.00062) and higher percentages of propionic (P value = 0.00433) and isovaleric (P value = 0.00433) acids compared to HC. Moreover, AP showed higher levels of propionic acid (P value = 0.03251) and a lower level of isobutyric acid (P value = 0.00427) in comparison to CRC. The PLS-DA model demonstrated a significant separation of CRC and AP groups from HC, although some degree of overlap was observed between CRC and AP. CONCLUSION: Analysis of fecal SCFAs shows the potential to provide a non-invasive means of diagnosis to detect patients with CRC and AP, while CD patients cannot be discriminated from healthy subjects. Baishideng Publishing Group Inc 2019-09-28 2019-09-28 /pmc/articles/PMC6767983/ /pubmed/31576099 http://dx.doi.org/10.3748/wjg.v25.i36.5543 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Observational Study
Niccolai, Elena
Baldi, Simone
Ricci, Federica
Russo, Edda
Nannini, Giulia
Menicatti, Marta
Poli, Giovanni
Taddei, Antonio
Bartolucci, Gianluca
Calabrò, Antonino Salvatore
Stingo, Francesco Claudio
Amedei, Amedeo
Evaluation and comparison of short chain fatty acids composition in gut diseases
title Evaluation and comparison of short chain fatty acids composition in gut diseases
title_full Evaluation and comparison of short chain fatty acids composition in gut diseases
title_fullStr Evaluation and comparison of short chain fatty acids composition in gut diseases
title_full_unstemmed Evaluation and comparison of short chain fatty acids composition in gut diseases
title_short Evaluation and comparison of short chain fatty acids composition in gut diseases
title_sort evaluation and comparison of short chain fatty acids composition in gut diseases
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767983/
https://www.ncbi.nlm.nih.gov/pubmed/31576099
http://dx.doi.org/10.3748/wjg.v25.i36.5543
work_keys_str_mv AT niccolaielena evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT baldisimone evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT riccifederica evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT russoedda evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT nanninigiulia evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT menicattimarta evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT poligiovanni evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT taddeiantonio evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT bartoluccigianluca evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT calabroantoninosalvatore evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT stingofrancescoclaudio evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases
AT amedeiamedeo evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases